Austin, TX – According to filings with the U.S. Securities and Exchange Commission, Direct Biologics is raising $11,569,702.00 in new funding. Sources indicate as part of senior management Executive, Mark Adams played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Direct Biologics

Direct Biologics is a market leading innovator and science-based manufacturer of regenerative products. Direct Biologics is a market leading innovator and cGMP manufacturer of regenerative biologic products, including ExoFlo™, a COVID-19 therapeutic geared solution, that leverages the regenerative properties of bone marrow mesenchymal stem cell (MSC)-derived extracellular vesicles. ExoFlo™ is currently used for investigational treatment of COVID-19 associated moderate-to-severe ARDS in an FDA approved clinical trial as well as an FDA approved Expanded Access Protocol for hospitals.

To learn more about Direct Biologics, visit http://directbiologics.com/

Contact:
Mark Adams, Executive
800-791-1021

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved